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Abstract
Background: The native articular cartilage lacks the ability to heal. Currently, ex vivo expanded chondrocytes or
bone marrow-derived mesenchymal stem cells are used to regenerate the damaged cartilage. With unlimited
self-renewal ability and multipotency, human induced pluripotent stem cells (hiPSCs) have been highlighted as a
new replacement cell source for cartilage repair. Still, further research is needed on cartilage regeneration using
cord blood mononuclear cell-derived hiPSCs (CBMC-hiPSCs).
Methods: Human iPSCs were generated from CBMCs using the Sendai virus. The characterization of CBMC-hiPSCs
was performed by various assays. Embryonic bodies (EBs) were obtained using CBMC-hiPSCs, and outgrowth cells
were induced by plating the EBs onto a gelatin-coated plate. Expanded outgrowth cells were detached and
dissociated for chondrogenic differentiation. Outgrowth cells were differentiated into chondrogenic lineage with
pellet culture. Chondrogenic pellets were maintained for 30 days. The quality of chondrogenic pellets was
evaluated using various staining and genetic analysis of cartilage-specific markers.
Results: Reprogramming was successfully done using CBMCs. CBMC-hiPSCs (n = 3) showed high pluripotency and
normal karyotype. Chondrogenic pellets were generated from the outgrowth cells derived from CBMC-hiPSC EBs.
The generated chondrogenic pellets showed high expression of chondrogenic genetic markers such as ACAN,
COMP, COL2A1, and SOX9. The production of extracellular matrix (ECM) proteins was confirmed by safranin O,
alcian blue and toluidine blue staining. Expression of collagen type II and aggrecan was detected in the
accumulated ECM by immunohistological staining. Chondrogenic pellets showed low expression of fibrotic and
hypertrophic cartilage marker, collagen type I and X.
Conclusions: This study reveals the potential of CBMC-hiPSCs as a promising candidate for cartilage regeneration.
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Background
The articular cartilage is an elastic, white tissue that
covers the end of bones and protects them from friction.
Cartilage is mostly composed of chondrocytes and a
large amount of extracellular matrix (ECM) rich in
various types of collagen, proteoglycan and elastic fibers
[1, 2]. Chondrocytes produce ECM components and trap
themselves in a small room called ‘lacuna’, making it
difficult to migrate and repair once the cartilage is dam-
aged. Moreover, cartilage is an avascular tissue, i.e., it
does not contain any blood vessels for nutrient supple-
mentation. The avascularity of cartilage also hampers
the migration of stem cells, reducing the regeneration
potential of the tissue. These reasons indicate that it is
almost impossible to naturally heal a damaged cartilage
[3]. Therefore it is important to generate functional
chondrocytes that can synthesize ECM in vitro or to
obtain a fully developed cartilage for transplantation.
Cartilage reconstruction is usually done by transplant-
ation using bone marrow-derived mesenchymal stem
cells (BMSCs) or native chondrocytes isolated from the
knee joint [4]. BMSCs and native chondrocytes have sev-
eral advantages in regeneration capacity, because of their
original chondrogenic potential. BMSCs are relatively
easy to be obtained and already widely used as a cellular
therapeutic material for various diseases including
rheumatoid arthritis and osteoarthritis [5–9]. The slow
rate of proliferation severely limits the regenerative po-
tential of the cartilage [10–12]. It is challenging to obtain
a high number of cells from in vitro culture of BMSCs
or chondrocytes because extensive expansion can alter
their phenotype [13–16]. Also, it was reported that the
yield and the differentiation ability of BMSCs was
reduced depending on the patient’s age and pathogenic
conditions [17, 18]. In the case of native chondrocytes,
additional damage to the knee joint is inevitable to
obtain these cells. For these reasons, a new cell source
for cartilage reconstruction is required.
It is important to generate hyaline cartilage for suc-
cessful cartilage transplantation. Hyaline cartilage is the
elastic type of cartilage, which is mostly made up of col-
lagen type II. Long-term observation reveals that the
transplanted chondrogenic cells tend to differentiate into
hypertrophic chondrocytes that result in fibrotic
cartilage-like phenotypes rather than hyaline cartilage
[19, 20]. Although cell-based therapy is commonly prac-
ticed in clinic, it has not been proved that BMSCs and
native chondrocytes can successfully repair the mature
human cartilage [21, 22]. Other than cell-based therapy,
mature cartilage transplantation by osteochondral graft-
ing is another option to treat severely damaged cartilage.
The advantage of osteochondral grafting is the trans-
plantation of mature hyaline cartilage [23]. One part of
the healthy cartilage of the joint is removed and
transferred to the damaged region. Allogeneic cartilage
transplantation has the risk of immunological rejection,
which can eventually affect the viability of the allografts.
Osteochondral autografting (mosaicplasty), however, is
subject to the availability of healthy donor sites and the
condition of the graft. These limitations still remain as
an interesting topic in cartilage regeneration and require
further studies by clinicians and researchers.
Human induced pluripotent stem cells (hiPSCs) have
been highlighted as an alternative cell source for regenera-
tive medicine. The discovery of hiPSCs provided a new
strategy for drug screening and mechanistic studies of
various diseases. Moreover, hiPSCs are a potential relevant
cell source for the replacement of damaged tissues that
have limited healing ability, such as the articular cartilage
[24, 25]. Unlike BMSCs or native chondrocytes, the use of
hiPSCs is highly recommended due to their high self-
renewal ability and capacity to differentiate into targeted
cells, including chondrocytes [26]. With the proper cul-
ture conditions, hiPSCs have greater potential as a re-
placement source to be used in cartilage regeneration.
In earlier reprogramming protocols, dermal fibroblasts
were used for iPSC generation. Yet, the surgical biopsy
procedure to obtain these cells restricted the opportun-
ity for broad applications. Dermal fibroblasts are also re-
ported to have higher genetic mutations due to exposure
to environmental factors [27]. Blood cells were recom-
mended as an alternative for reprogramming. Compared
to fibroblasts, blood cells are a relatively accessible cell
source. Blood cell-derived hiPSCs were successfully
achieved with various reprogramming technologies
[28–30]. These attempts were equally successful with
cord blood mononuclear cells (CBMCs) [31–35].
In this study, we used CBMC-derived human iPSCs
(CBMC-hiPSCs) for further experiments. Recently,
CBMC-hiPSCs were successfully differentiated into car-
diomyocytes and hepatocytes [17, 36, 37]. Previous work
done by Guzzo et al., has shown the potential of CBMC-
hiPSCs in chondrogenesis using micromass culture [38].
However, there is still much unknown about the chon-
drogenic regeneration ability of CBMC-hiPSCs, requir-
ing further research. Chondrogenic pellets generated
from CBMC-hiPSCs can be further used as a regenera-
tive medicine in clinic. To achieve this goal, cartilage
regeneration was attempted by pellet culture using
CBMC-hiPSCs. Generated CBMC-hiPSCs were aggre-
gated into embryoid bodies (EBs) and mesenchymal-like
outgrowth cells were induced by attaching the EBs to a
gelatin-coated dish. Chondrogenic pellets were
generated using EB outgrowth cells.
Herein, we report the characteristics of cartilage-like
chondrogenic pellets generated from CBMC-hiPSCs that
indicate the possibility as a potential cell source for car-
tilage regeneration for future applications.
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Methods
CBMC isolation
CBMCs were directly obtained from the Cord Blood
Bank of the Seoul St. Mary’s Hospital. Cord blood was
diluted with phosphate-buffered saline (PBS) and centri-
fuged through Ficoll gradient (GE Healthcare, Little
Chalfont, UK) for 30 minutes at 850 × g. CBMCs were
collected, washed, and frozen. Prior to being used,
frozen CBMCs were thawed and resuspended in Stem-
Span medium (Stemcell Technologies, Vancouver, BC,
Canada) supplemented with CC110 cytokine cocktail
(Stemcell). Cells were maintained for 5 days at 5% CO2,
37 °C before reprogramming.
Blood sample and ethics statement
The Institutional Review Board (IRB) of the Catholic
University of Korea, Seoul St. Mary’s Hospital approved
this study.
Reprogramming using Sendai virus
The generation of hiPSCs was followed by the proce-
dures mentioned in our previous work [35]. CBMCs
were counted (3 × 105) and seeded in one well of a 24-
well plate. CytoTune-iPS Sendai Reprogramming Kit
(Life Technologies, Carlsbad, CA, USA) was used to in-
duce reprogramming. Transduction was performed with
multiplicity of infection 7.5 per 3 × 105 cell infectious
units. After adding the viral components, cells were cen-
trifuged at 1160 × g, 35 °C for 30 minutes and incubated
at 5% CO2, 37 °C. On the following day, cells were trans-
ferred to a vitronectin-coated 12-well plate (Life Tech-
nologies) and settled by centrifugation for 10 minutes at
1160 × g, 35 °C. TeSR-E8 medium (Stemcell) was added
(1:1) after centrifugation. Reprogrammed cells were
maintained and expanded in TeSR-E8 media with daily
media change.
Alkaline phosphatase staining
To achieve colonies large enough for staining, 2 × 103
cells were seeded in one well of a vitronectin-coated
6-well plate and expanded for 5–7 days. Staining of un-
differentiated iPSC colonies was done using an alkaline
phosphatase detection kit (EMD Millipore, Billerica,
MA, USA). Cells were washed with PBS containing
0.05% Tween-20 (PBST; Biosesang, Seongnam, Korea)
and fixed with 4% paraformaldehyde (Biosesang) for
2 minutes. Staining reagents including Fast Red Violet,
Naphthol AS-BI phosphate solution, and water were
mixed in a 2:1:1 ratio. Cells were washed twice with
PBST. The staining solution mixture was treated for
15 minutes at room temperature (RT). After incubation,
cells were washed with PBST and covered with PBS to
prevent drying. Stained colonies were surveyed under
the microscope.
Immunocytochemical staining
To achieve large hiPSC colonies, 2 × 103 cells were
seeded per one well of a vitronectin-coated 6-well plate.
Cells were expanded for 5–7 days with daily media
change to induce large hiPSC colonies. After expansion,
hiPSCs were washed with PBS and fixed with 4% para-
formaldehyde. Cells were permeabilized using 0.1% tri-
ton X-100 (Biosesang) for 10 minutes. After
permeabilization, cells were blocked for 30 minutes in
RT with PBS containing 2% bovine serum albumin
(BSA; Sigma-Aldrich, St. Louis, MO, USA) (PBA). Pri-
mary antibodies were diluted in PBA with the following
dilution ratios; OCT4 (1/100; Santa Cruz Biotechnology,
Dallas, TX, USA), KLF4 (1/250; Abcam, Cambridge,
UK), SOX2 (1/100; BioLegend, San Diego, CA, USA),
TRA-1-60 (1/100; EMD Millipore), TRA-1-81 (1/100;
EMD Millipore), and SSEA4 (1/200; EMD Millipore).
Primary antibodies were incubated for 2 hours at RT.
Alexa Fluor 594- (1/400; Life Technologies) and
488-conjugated secondary antibodies (1/400; Life
Technologies) were diluted in PBA and incubated for
1 hour at RT avoiding light. Cells were washed and
mounted using ProLong Antifade mounting reagent
(Thermo Fisher Scientific, Waltham, MA, USA). Stained
colonies were detected with an immunofluorescence
microscope.
Polymerase chain reaction using CBMC-iPSC samples
5 × 105 iPSCs were harvested and frozen in -20 °C. Total
mRNA was extracted using Trizol (Life Technologies)
and cDNA was synthesized using RevertAid™ First
Strand cDNA Synthesis Kit (Thermo Fisher Scientific).
Reverse transcriptase polymerase chain reaction was
conducted using the synthesized cDNAs. Primer se-
quences are shown in the Table 1.
Karyotyping
Cells were cultured and expanded until 80% confluent.
Chromosome resolution additive (Genial Genetic Solu-
tions, Runcorn, UK) was added to each well. Cells were
treated with Colcemid® for 30 minutes. Cells were har-
vested and treated with pre-warmed hypotonic solution.
Fixation was performed with a 1:3 mixture of acetic acid
to methanol solution. Slides were prepared for chromo-
some analysis using trypsin-Giemsa banding technique.
Functional identification of iPSCs
To assess the three germ layer differentiation ability, a
Human Pluripotent Stem Cell Functional Identification
Kit was purchased (R&D Systems, Minneapolis, MN,
USA). One day before the experiment, Cultrex PathClear
BME (R&D Systems) was coated onto the culture dishes
following the manufacturer’s instructions. Medium spe-
cific to each germ layer was prepared, and cells were
Nam et al. Stem Cell Research & Therapy  (2017) 8:16 Page 3 of 13
cultured individually. After differentiation, cells were
washed with PBS and fixed with 4% paraformaldehyde.
Permeabilization and blocking was conducted with 0.3%
Triton X-100 and 1% PBA for 45 minutes. Antibody
against Otx2 (1/10; ectoderm), Brachyury (1/10; meso-
derm), and Sox17 (1/10; endoderm) was diluted in PBA
and incubated for 3 hours at RT. After washing the pri-
mary antibodies, Alexa Fluor 568 donkey anti-goat
secondary antibody (1:200; R&D Systems) was diluted in
PBA and incubated for 1 hour. Cells were washed with
PBA, and treated with DAPI solution for 10 minutes in
RT. Cells were washed and covered with PBS. Staining
results were confirmed using fluorescence microscopy.
EB-derived outgrowth cell induction
CBMC-hiPSCs were expanded and 2 × 106 cells were
prepared. Cells were resuspended in Aggrewell medium
(Stemcell) and plated onto a 100-mm petri dish. Cells
were incubated overnight at 5% CO2, 37 °C. The next
day, media was changed into TeSR-E8 medium and cells
were maintained for 6 days for expansion. After the ex-
pansion process, EBs were harvested and resuspended in
DMEM containing 20% fetal bovine albumin (FBS) and
placed on a gelatin-coated dish to induce outgrowth
cells. Cells were maintained at 5% CO2, 37 °C for a week
before chondrogenic differentiation.
Chondrogenic differentiation using EB-derived outgrowth
cells
Outgrowth cells derived from EBs were washed and
detached from the dish. Cell clumps were removed by
passing through a 40 μm cell strainer (Thermo Fisher
Scientific). Single outgrowth cells were counted and 3 ×
105 cells per pellet were prepared. 3 × 105 outgrowth
cells were resuspended in chondrogenic differentiation
medium (DMEM, 20% knockout serum replacement,
1 × non-essential amino acids, 1 mM L-glutamine, 1%
sodium pyruvate, 1% ITS+ Premix, 10-7M dexametha-
sone, 50 mM ascorbic acid, 40 μg/mL L-proline supple-
mented with 50 ng/mL human bone morphogenetic
protein 2 and 10 ng/mL human transforming growth
factor beta 3) and transferred to a 15 mL conical tube.
Cells were centrifuged at 750 × g for 5 minutes. Gener-
ated pellets were maintained for 30 days and media was
changed every other day. BMSCs were used as a positive
control.
Histological analysis of chondrogenic pellet
Pellets were fixed in 4% paraformaldehyde for 2 hours at
RT. One layer of gauze was placed onto a cassette and
pellets were transferred onto the gauze. Dehydration was
performed with sequential ethanol solutions. Dehydra-
tion solutions were cleared with graded ethanol and
zylene mixtures (Duksan Pure Chemicals, Ansan, Korea)
and paraffin was infiltrated overnight. The next day,
pellets were fixed to a paraffin block and 7 μm sections
were obtained using a microtome. Slides were dried for
10 minutes at 60 °C. Sections were deparaffinized by two
cycles of zylene. Sections were rehydrated with decreas-
ing sequential ethanol series and sections were rinsed
under running tap water for 5 minutes. For alcian blue
staining, sections were incubated in 1% alcian blue
solution for 30 minutes. Slides were washed and coun-
terstained with nuclear fast red for 1 minute. Safranin O
staining was performed by incubating the slides in
Weigert’s iron hematoxylin for 10 minutes. Slides were
washed and incubated in 0.1% safranin O solution for
5 minutes. Finally, for toluidine staining, sections were
incubated in 0.04% toluidine blue solution for 4 minutes.
After the staining process, sections were washed and
passed through increasing sequential ethanol series.
Ethanol was cleared with two cycles of zylene and slides
were mounted using VectaMount™ Permanent Mounting
Medium (Vector Laboratories, Burlingame, CA, USA).
Staining was confirmed under a bright field microscope.
Immunohistochemistry
Sections were dried for 10 minutes at 60 °C and deparaf-
finized by two cycles of zylene. Sections were rehydrated
with decreasing sequential ethanol series and sections
were rinsed under running tap water for 5 minutes.
Antigen unmasking was induced by incubating the sec-
tions in boiling citrate buffer (Sigma-Aldrich) for 15 -
minutes and leaving them to cool for 20 minutes.
Cooled sections were then washed twice with deionized
water (DW). The activity of endogenous peroxidase was
blocked by incubating the sections in 3% hydrogen
Table 1 Sequences of primers against pluripotent markers used
in real time RT-PCR
Target name Direction Primer sequence Size
OCT3/4 Forward ACCCCTGGTGCCGTGAA 190
Reverse GGCTGAATACCTTCCCAAATA
SOX2 Forward CAGCGCATGGACAGTTAC 321
Reverse GGAGTGGGAGGAAGAGGT
NANOG Forward AAAGGCAAACAACCCACT 270
Reverse GCTATTCTTCGGCCAGTT
LIN28 Forward GTTCGGCTTCCTGTCCAT 122
Reverse CTGCCTCACCCTCCTTCA
DPPB5 Forward CGGCTGCTGAAAGCCATTTT 215
Reverse AGTTTGAGCATCCCTCGCTC
TDGF1 Forward TCCTTCTACGGACGGAACTG 140
Reverse AGAAATGCCTGAGGAAAGCA
GAPDH Forward GAATGGGCAGCCGTTAGGAA 414
Reverse GACTCCACGACGTACTCAGC
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peroxide (Sigma-Aldrich) diluted in DW for 10 minutes.
Sections were washed in DW twice, followed with
additional washing with tris-buffered saline (TBS) con-
taining 0.1% tween-20 (TBST). Sections were blocked
for 20 minutes at RT with TBS containing 1% BSA. Pri-
mary antibodies diluted in blocking solution were added
to the sections and incubated overnight at 4 °C. Primary
antibodies were diluted in the following ratios: collagen
type I (1/100; Abcam), collagen type II (1/100; Abcam)
and Aggrecan (1/100; GeneTex, Irvine, CA, USA). Nega-
tive control slides were treated with the same amount of
blocking solution without antibodies. The next day, sec-
tions were washed in TBST three times, each for 3 mi-
nutes, and secondary antibodies (1/200; Vector
Laboratories) were applied for 40 minutes at RT.
Sections were washed with TBST and incubated in ABC
reagent (Vector Laboratories) for 30 minutes. Slides
were washed with TBST three times and DAB solution
(Vector Laboratories) was applied for 1 minute. Sections
were washed in DW until the color was rinsed. Mayer’s
hematoxylin (Sigma-Aldrich) was applied to the sections
for 1 minute for counterstaining. Sections were washed
and passed through increasing sequential ethanol series.
Ethanol was cleared with two cycles of zylene and slides
were mounted using VectaMount™ Permanent Mounting
Medium (Vector Laboratories). Staining was confirmed
under a bright field microscope.
Polymerase chain reaction with chondrogenic pellet
samples
Ten chondrogenic pellets were harvested on each time
point and frozen at −80 °C. Samples were snap-frozen
with liquid nitrogen and ground with a pestle. Ground
pellet samples were incubated with Trizol for mRNA ex-
traction. From the extracted mRNAs, cDNA was synthe-
sized and polymerase chain reaction was conducted with
primers against chondrocyte-specific markers. Primer se-
quences for RT-PCR are provided in Table 2. Primer
sequences for real time-PCR are provided in Table 3.
Mean cycle threshold values from triplicate experiments
were used to calculate the gene expression normalized
to GAPDH as an internal control.
Results
Generation of hiPSCs using isolated CBMC
Reprogramming of CBMC was induced using Sendai
virus containing Yamanaka factors. With several pas-
sages after transduction, CBMC-hiPSCs showed embry-
onic stem cell-like colonies during expansion (Fig. 1a).
CBMC-hiPSCs were maintained and purified until cell
lines had homogenous cell morphology. Homogenous
CBMC-hiPSCs were used for further characterization.
Established CBMC-hiPSCs exhibited positive alkaline
phosphatase staining (Fig. 1b). The relative expression of
pluripotent markers including OCT4, SOX2, NANOG,
LIN28, KLF4, and c-MYC was assessed (Fig. 1c). Paren-
tal CBMC was used as a negative control. The expres-
sion of OCT4, SOX2, NANOG, and Lin28 was increased
in CBMC-hiPSCs. The expression of KLF4 and c-MYC,
however, was lower in CBMC-hiPSCs than that of
CBMCs. Typical cell surface markers (SSEA4, OCT4,
SOX2, KLF4, TRA-1-80, and TRA-1-60) were confirmed
by immunocytochemical analysis (Fig. 1d). All generated
cell lines expressed the canonical markers of pluripo-
tency. We confirmed that CBMC-hiPSCs maintained
normal karyotypes after the reprogramming process (see
Additional file 1a). CBMC-hiPSCs were also able to dif-
ferentiate into each germ layer (see Additional file 1b).
Together, these data suggested that CBMC-hiPSCs were
Table 2 Sequences of primers against chondrogenic markers in
RT-PCR
Target name Direction Primer sequence Size
SOX9 Forward GAACGCACATCAAGACGGAG 631
Reverse TCTCGTTGATTTCGCTGCTC
ACAN Forward TGAGGAGGGCTGGAACAAGTACC 349
Reverse GAGGTGGTAATTGCAGGGAACA
COL2A1 Forward TTCAGCTATGGAGATGACAATC 472
Reverse AGAGTCCTAGAGTGACTGAG
COMP Forward CAACTGTCCCCAGAAGAGCAA 588
Reverse TGGTAGCCAAAGATGAAGCCC
COL1A1 Forward CCCCTGGAAAGAATGGAGATG 148
Reverse TCCAAACCACTGAAACCTCTG
COL10 Forward CAGTCATGCCTGAGGGTTTT 196
Reverse GGGTCATAATGCTGTTGCCT
GAPDH Forward GAATGGGCAGCCGTTAGGAA 414
Reverse GACTCCACGACGTACTCAGC
Table 3 Sequences of primers against chondrogenic markers in
real time-PCR
Target name Direction Primer sequence Size
SOX9 Forward TTCCGCGACGTGGACAT 77
Reverse TCAAACTCGTTGACATCGAAGGT
ACAN Forward AGCCTGCGCTCCAATGACT 107
Reverse TAATGGAACACGATGCCTTTCA
COL2A1 Forward GGCAATAGCAGGTTCACGTACA 79
Reverse CGATAACAGTCTTGCCCCACTTA
COMP Forward AGCAGATGGAGCAAACGTATTG 76
Reverse ACAGCCTTGAGTTGGATGCC
COL1A1 Forward CCCCTGGAAAGAATGGAGATG 148
Reverse TCCAAACCACTGAAACCTCTG
COL10 Forward CAGTCATGCCTGAGGGTTTT 196
Reverse GGGTCATAATGCTGTTGCCT
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successfully generated and the cells exhibited the genu-
ine characteristic of pluripotency.
Chondrogenic differentiation of CBMC-iPSCs
To confirm the cartilage regeneration ability of CBMC-
hiPSCs, we performed chondrogenic differentiation
through EB culture and outgrowth cell induction. A sim-
ple scheme of the chondrogenic pellet generation
process is shown in Fig. 2a. Colonies of CBMC-hiPSCs
were prepared for chondrogenic differentiation (Fig. 2b).
CBMC-hiPSCs were expanded and aggregated into EBs
(Fig. 2c). EBs were enlarged for several days and trans-
ferred to gelatin-coated dishes to induce outgrowth cells
(Fig. 2d). Outgrowth cells were expanded and dissociated
into single cells for chondrogenic differentiation. Using
2 × 106 iPSCs, numerous chondrogenic pellets were
obtained (Fig. 2e). After 30 days of differentiation, chon-
drogenic pellets were generated using EB outgrowth
cells. The generated chondrogenic pellets exhibited a
three-dimensional spheroid configuration. Throughout
this process, we confirmed that CBMC-hiPSCs were able
to differentiate into chondrocytes and formed a
spheroid-shaped cartilage-like appearance by ECM
accumulation.
Confirmation of chondrogenic gene expression
Previously, chondrogenic pellets were successfully gener-
ated from CBMC-hiPSCs. Also, the differentiated cells
were able to synthesize ECM components and exhibit
cartilage-like features. We examined the gene expression
of major ECM component proteins such as aggrecan
(ACAN), collagen type II (COL2A1), and cartilage
Fig. 1 Characterization of three CBMC-hiPSC lines. a Morphology of the three generated CBMC-hiPSC lines. b CBMC-hiPSC colonies positively
stained with alkaline phosphatase. c Relative expression of pluripotent markers in each CBMC-hiPSC line. Primary CBMC was used as a control.
d Immunofluorescence staining image of the generated CBMC-hiPSC lines. All scale bars represent 200 μm. CBMC-hiPSC cord blood mononuclear
cell-derived human induced pluripotent stem cell
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oligomeric matrix protein (COMP) on several time
points (day 10, 20, and 30). The increasing expression of
ACAN, COL2A1, and COMP was confirmed (Fig. 3).
Sex-determining region Y-box 9 (SOX9) is known as an
early chondrogenic marker and a transcription factor
that regulates the expression of ECM protein genes. The
expression of SOX9 significantly increased after day 20.
According to these results, we confirmed the genetic
characteristics of the generated chondrogenic pellets.
Corresponding to the cartilage-like morphology, the in-
creased gene expression of major ECM component pro-
teins was confirmed.
Histological characterization of chondrogenic pellets
According to the confirmation of increased chondro-
genic marker expression, the protein levels of the chon-
drogenic pellets generated from CBMC-hiPSCs were
evaluated by histological analysis (Fig. 4). Safranin O,
alcian blue, and toluidine blue staining are authorized
staining methods for ECM detection in cartilage. With
the staining results, we confirmed ECM accumulation at
the lining of the pellets even on the early stage of differ-
entiation (day 10). Lacunae are one of the major features
shown in the articular cartilage. Hollow lacuna-like cap-
acities were visible after day 10. The size, however,
Fig. 3 Genetic characterization of chondrogenic pellet generated from CBMC-hiPSCs. The expression of COL2A1, ACAN, COMP, and SOX9 in day
10, 20, and 30 chondrogenic pellets. Data was obtained using RT-PCR and band intensity was evaluated. (*, +p < 0.05, **, ++p < 0.01, ***, +++p <
0.001). ACAN aggrecan gene, COL2A1 collagen type II gene, COMP cartilage oligomeric matrix protein gene, hiPSC human induced pluripotent
stem cell, SOX9 sex-determining region Y-box 9 gene
Fig. 2 Chondrogenic pellet generation using CBMC-hiPSCs. a Scheme of chondrogenic pellet generation. b Morphology of CBMC-hiPSC.
c Morphology of generated EBs. d Image of outgrowth cells derived from EBs attached to a gelatin-coated culture dish. e Image of chondrogenic
pellets. All scale bars represent 200 μm. EB embryoid body, hiPSC human induced pluripotent stem cell
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decreased as differentiation progressed. On day 30 of
differentiation, as the ECM was accumulated in the cap-
acities, it appeared more like a lacuna in the articular
cartilage. The staining intensity of day 30 pellets was al-
most similar to that of MSC controls.
The quality of cartilage is dependent on the major type
of ECM proteins. Therefore, it is important to identify
the specific proteins that comprise the ECM. Aggrecan
and collagen type II proteins are known as the major
components that constitute the ECM. Collagen type II is
the dominant collagen type that represents the hyaline
cartilage. We specifically stained chondrogenic pellets
with antibody against collagen type II and aggrecan
(Fig. 5a). The staining intensity of collagen type II was
higher in CBMC-hiPSC-derived chondrogenic pellets
than that of MSC controls. Corresponding to the previ-
ous staining results, aggrecan and collagen type II was
mostly detected at the pellet lining on day 30. The major
characteristic of fibrotic cartilage is the high expression
of collagen type I. We confirmed that the generated pel-
lets did not have dominant characteristics of the fibrotic
cartilage (Fig. 5b). The expression of collagen type I was
relatively higher than that of MSC control pellets. Yet,
the expression maintained a constant level and did not
significantly increase during differentiation. Taken all to-
gether, chondrogenic pellets generated from CBMC-
hiPSCs featured similar qualities of pellets derived from
MSCs after 30 days of differentiation. Chondrocytes
differentiated from CBMC-hiPSCs were able to produce
ECM component proteins. CBMC-hiPSC-derived chon-
drogenic pellets had higher expression of collagen type
II than that of collagen type I. In conclusion, we con-
firmed that CBMC-hiPSCs were able to generate
cartilage-like features, which were similar to the charac-
teristics of hyaline cartilage.
Further analysis of genetic markers in chondrogenic
pellets derived from CBMC-hiPSCs and MSCs
Collagens are the most abundant proteins that compose
the ECM. Various types of collagen exist, however, colla-
gen type I, II, and X are mainly related to the cartilage.
Previously, we confirmed the expression of collagen type
I and type II by histochemical analysis (Fig. 5a and b).
Based on these results, the expression of collagen type I
gene (COL1A1) was further analyzed (Fig. 6a). The gene
expression of collagen type X (COL10), a protein known
as the dominant type expressed in hypertrophic cartil-
age, was analyzed as well. We confirmed the steady ex-
pression of collagen type I with histochemical staining.
The expression of COL1A1, however, decreased at each
time point. The expression of COL10 was not altered
during differentiation. As mentioned earlier, the ratio of
collagen type I to II can alter the outcome characteristic
of the chondrogenic pellet. Using the previous gene ex-
pression data, we evaluated the gene expression ratio of
COL2A1 to COL1A1 (Fig. 6b). The overall increasing
Fig. 4 Histological analysis of CBMC-hiPSC-derived chondrogenic pellet. Image of pellets stained by safranin O, alcian blue, and toluidine blue on
day 10, 20, and 30. All scale bars represent 100 μm. BMSC bone marrow-derived mesenchymal stem cell
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ratio indicates higher expression of hyaline cartilage
gene against fibrotic cartilage gene.
CBMC-hiPSC-derived chondrogenic pellets was com-
pared with chondrogenic pellets generated from BMSCs
on day 30 using real time-PCR (Fig. 6c). There was no
statistical significance of ACAN expression between the
two samples. The expression of COL2A1 and SOX9 was
significantly higher in the chondrogenic pellets differen-
tiated from CBMC-hiPSCs compared to BMSC-derived
pellets. Yet, COMP was highly expressed in MSC control
pellets. The expression of the fibrotic marker, COL1A1,
was higher in MSC control pellets as well. The expres-
sion of the hypertrophic marker COL10, however, was
remarkably lower in the CBMC-hiPSC-derived chondro-
genic pellets. These results highlight the possibility of
CBMC-hiPSCs as a potential cell source for cartilage
regeneration and further future applications.
Discussion
The repair of articular cartilage injury caused by
joint-related diseases, external wound, or trauma still
remains an unsolved clinical issue. Human iPSCs
opened new possibilities for regeneration of personal-
ized medicine. Numerous groups attempted chondro-
genesis using hiPSCs generated from various somatic
cell types [38–42].
We reprogrammed CBMCs into hiPSCs using Sendai
viral vectors containing Yamanaka factors (Fig. 1a) [35].
Due to the established cord blood banking system
around the world, CBMCs are widely utilized. The con-
version of cord blood banks into hiPSC banks for allo-
geneic regenerative medical treatment holds tremendous
potential and possibilities [43]. With the database of
HLA phenotypes, a CBMC-based hiPSC banking system
can give a new efficient strategy for cell-based therapy
by generating cell lines with homozygous HLA-typed
hiPSCs. Homozygous cell lines can be widely utilized in
treatment with minimum material or cell lines. This
concept can be equally applied to cartilage regeneration.
Generation of cartilage using HLA-homozygous hiPSC
lines can eliminate the immunological reactions when
applied in allograft transplantation. Therefore, the use of
CBMC-hiPSCs can be highly efficient for future applica-
tion in cartilage transplantation. Many reports demon-
strated that the origin of the somatic cell used in
reprogramming, can affect the developmental and differ-
ential ability [44–46]. Guzzo et al. highlighted the poten-
tial of CBMC-hiPSCs for chondrogenic differentiation
[38]. This work was done with one CBMC-hiPSC line
and two articular chondrocyte-derived hiPSC lines.
However, additional study is required to further identify
CBMC-hiPSCs as an ideal cell source for cartilage
Fig. 5 Immunohistological analysis of CBMC-hiPSC-derived chondrogenic pellets. a Image of pellet harvested at various time points stained with
antibody against collagen type II and aggrecan. b Image of pellet stained with antibody against collagen type I. All scale bars represent 100 μm.
BMSC bone marrow-derived mesenchymal stem cell
Nam et al. Stem Cell Research & Therapy  (2017) 8:16 Page 9 of 13
regeneration and transplantation. We attempted chon-
drogenic differentiation using CBMC-hiPSCs (n = 3) and
analyzed the cartilage regeneration ability by various as-
says. For future application in transplantation, chondro-
genic differentiation was performed by pellet culture.
Prior to the differentiation process, the characteristics
of the generated CBMC-hiPSCs were analyzed. The un-
differentiated stem cell characteristic was confirmed by
the positive staining against alkaline phosphatase
(Fig. 1b). Increased expression of pluripotent markers
was confirmed by immunocytochemical and cytogenetic
assays (Fig. 1c and d). All cell lines were able to differen-
tiate into each germ layer and featured a normal karyo-
type (see Additional file 1).
Chondrogenic differentiation is performed through
two critical steps: induction of mesenchymal-like
Fig. 6 Further analysis of genetic markers in chondrogenic pellets derived from CBMC-hiPSCs and MSCs. a The expression of fibrotic cartilage
representative gene, COL1A1 and hypertrophic marker, COL10 at various time points. b The ratio of COL2A1 and COL1A1 at day 10, 20, and 30.
c The relative expression of ACAN, COMP, COL2A1, SOX9, COL1A1, and COL10 in chondrogenic pellets derived from BMSC and CBMC-hiPSC on
day 30. (*,+p < 0.05, **,++p < 0.01, ***,+++p < 0.001). ACAN aggrecan gene, COL10 collagen type 10 gene, COL1A1 collagen type I gene, COL2A1
collagen type II gene, COMP cartilage oligomeric matrix protein gene, iPSC induced pluripotent stem cell, MSC mesenchymal stem cell, SOX9
sex-determining region Y-box 9 gene
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outgrowth cells and chondrogenic pellet formation. Pre-
vious studies confirmed that outgrowth cells generated
from hiPSCs are functionally and molecularly similar to
native MSCs [47, 48]. These studies used monolayer cul-
ture or EB culture as a pre-differentiation step to induce
mesenchymal-like progenitor cells [48, 49]. Direct differ-
entiation using monolayer culture, however, was time-
consuming compared to the use of EBs. The morphology
and differentiation potential of mesenchymal-like
progenitor cells also differed greatly according to the cell
density [50].
Based on these considerations, we used EBs to induce
mesenchymal-like outgrowth cells (Fig. 2a). Using only
2 × 106 cells, a large amount of EBs was prepared (Fig. 2b).
To generate outgrowth cells, maintained EBs were plated
onto gelatin-coated dishes for expansion. Seeding 50–
75 EB per cm2 was adequate for the proper density of out-
growth cells (Fig. 2c). Chondrogenic pellets were gener-
ated by pellet culture using the outgrowth cells (Fig. 2d).
We were able to obtain 50–100 pellets in total (Fig. 2e).
The quality of the generated chondrogenic pellets, how-
ever, is as important as the quantity. The expression of
several specific genes for ECM proteins was confirmed.
ACAN is a proteoglycan that forms aggregates in the
ECM, and induces the interaction with hyaluronan [51].
COL2A1 is the fundamental protein for hyaline cartilage
that represents the non-hypertrophic characteristic of a
healthy cartilage [52]. The expression of ACAN and
COL2A1 significantly increased on day 10 (Fig. 3). The ex-
pression of COMP, which is a non-collagenous ECM pro-
tein started to increase sharply on day 20. It was reported
that the overexpression of COMP increased the levels of
ACAN and COL2A1, however, the expression of the early
chondrogenic marker, SOX9, was not affected by the in-
creased COMP expression [53]. In our study, the expres-
sion of SOX9 increased in the same pattern as COMP. By
several cartilage-specific staining methods, we confirmed
that the ECM components were accumulated as much as
those of cartilage generated from MSCs on day 30 (Fig. 4).
After generating cartilage, it is critical to distinguish
hyaline cartilage from fibrotic cartilage. Fibrotic, or
hypertrophic cartilage, is a further mature type that
tends to differentiate into bone [54]. The generated
chondrogenic pellet from CBMC-hiPSCs showed rela-
tively low expression of hypertrophic markers (Fig. 6a).
Expression of COL1A1 was decreasing while COL2A1
expression increased throughout differentiation (Fig. 6b).
The property of chondrogenic pellets derived from
CBMC-hiPSCs was compared to that of pellets derived
from BMSCs on day 30 (Fig. 6c). The expression of
COL2A1 and SOX9 significantly increased in pellets
generated from CBMC-hiPSCs. Interestingly, the expres-
sion of COMP was higher in the chondrogenic pellets
generated from BMSCs. Also, the expression of COL1A1
and COL10 was increased in pellets derived from
BMSCs as well. COMP is thought as one of the essential
proteins that exist in the tendon and cartilage. It pro-
vides adaptor function and binds directly to collagen
type I and XII, which is a protein that decorates the sur-
face of collagen I fibrils [55]. It is also considered as a
marker of cartilage breakdown [56]. Recently, COMP is
also thought as a biological marker for several diseases
with high cartilage turnover rates such as rheumatoid
arthritis and systemic sclerosis [54, 56–58]. This indi-
cates that CBMC-hiPSCs might have less fibrotic or
hypertrophic cartilage properties compared to BMSC-
derived chondrogenic pellets.
We confirmed that the cartilage regenerated using
CBMC-hiPSCs showed a healthy phenotype and can be
considered a material for tissue regeneration. Yet, an im-
proved method with a shorter differentiation time line is
required for further applications. Further development
of quality control standards to validate cartilage with
higher hyaline is also required for future applications of
CBMC-hiPSCs as cell material for cartilage regeneration.
Conclusions
CBMC-hiPSCs can be used as a material for cartilage re-
generation. CBMC-hiPSCs can open new possibilities for
personalized regenerative medicine.
Additional file
Additional file 1: Further characterization of three hiPSC lines
generated from CBMCs. a Karyotype images of the generated
CBMC-hiPSCs. b Immunofluorescence image of CBMC-hiPSCs
differentiated to ectoderm (Otx2), mesoderm (Brachyury) and endoderm
(Sox17). All scale bars represent 200 μm. (PDF 278 kb)
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